K Le Blanc

Summary

Affiliation: Huddinge University Hospital
Country: Sweden

Publications

  1. ncbi request reprint Mesenchymal stem cells: progress toward promise
    K Le Blanc
    Department of Laboratory Medicine, Division of Clinical Immunology, Karolinska Institutet, Stockholm, Sweden
    Cytotherapy 7:36-45. 2005
  2. ncbi request reprint Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes
    Ida Rasmusson
    Division of Clinical Immunology, Karolinska University Hospital, SE 141 86 Stockholm, Sweden
    J Leukoc Biol 82:887-93. 2007
  3. pmc Prophylaxis of acute GVHD: manipulate the graft or the environment?
    A John Barrett
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Best Pract Res Clin Haematol 21:165-76. 2008
  4. ncbi request reprint Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
    Katarina Le Blanc
    Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Lancet 363:1439-41. 2004
  5. ncbi request reprint [Mesenchymal stem cells. Basic science and future clinical use]
    Katarina Le Blanc
    Hematologiska kliniken, Huddinge Universitetssjukhus
    Lakartidningen 99:1318-21, 1324. 2002
  6. ncbi request reprint Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex
    K Le Blanc
    Division of Clinical Immunology Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Scand J Immunol 57:11-20. 2003
  7. ncbi request reprint Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Transplantation 79:1607-14. 2005
  8. ncbi request reprint A low body mass index is correlated with poor survival after allogeneic stem cell transplantation
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, F79, Karolinska Institutet, Huddinge University Hospital, SE 141 86, Stockholm, Sweden
    Haematologica 88:1044-52. 2003
  9. ncbi request reprint Mesenchymal stromal cells: Tissue repair and immune modulation
    K Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Cytotherapy 8:559-61. 2006
  10. ncbi request reprint Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation
    Katarina Le Blanc
    Division of Clinical Immunology, F79 Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Haematologica 90:438. 2005

Collaborators

Detail Information

Publications57

  1. ncbi request reprint Mesenchymal stem cells: progress toward promise
    K Le Blanc
    Department of Laboratory Medicine, Division of Clinical Immunology, Karolinska Institutet, Stockholm, Sweden
    Cytotherapy 7:36-45. 2005
    ..We believe MSC continue to provide a substantial scientific and therapeutic opportunity, and have reviewed some of the recent developments in the field...
  2. ncbi request reprint Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes
    Ida Rasmusson
    Division of Clinical Immunology, Karolinska University Hospital, SE 141 86 Stockholm, Sweden
    J Leukoc Biol 82:887-93. 2007
    ..These data may have important implications for the development of therapeutic strategies based on administration of in vitro-expanded MSCs...
  3. pmc Prophylaxis of acute GVHD: manipulate the graft or the environment?
    A John Barrett
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Best Pract Res Clin Haematol 21:165-76. 2008
    ....
  4. ncbi request reprint Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
    Katarina Le Blanc
    Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Lancet 363:1439-41. 2004
    ..Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo...
  5. ncbi request reprint [Mesenchymal stem cells. Basic science and future clinical use]
    Katarina Le Blanc
    Hematologiska kliniken, Huddinge Universitetssjukhus
    Lakartidningen 99:1318-21, 1324. 2002
    ....
  6. ncbi request reprint Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex
    K Le Blanc
    Division of Clinical Immunology Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Scand J Immunol 57:11-20. 2003
    ..The effect of a larger number of MSCs on MLCs seems more dependent on cell dose than histocompatibility and could result from an 'overload' of a stimulatory mechanism...
  7. ncbi request reprint Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Transplantation 79:1607-14. 2005
    ..Adult human leukocyte antigen (HLA)-matched MSC have been used in cellular therapies of bone disorders such as osteogenesis imperfecta, with promising results...
  8. ncbi request reprint A low body mass index is correlated with poor survival after allogeneic stem cell transplantation
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, F79, Karolinska Institutet, Huddinge University Hospital, SE 141 86, Stockholm, Sweden
    Haematologica 88:1044-52. 2003
    ..The purpose of this study was to determine whether body mass index (BMI, kg body weight/height (in m2) is related to survival in recipients of allogeneic stem cell transplantation (ASCT)...
  9. ncbi request reprint Mesenchymal stromal cells: Tissue repair and immune modulation
    K Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Cytotherapy 8:559-61. 2006
    ..Possible clinical indications include therapy-resistant severe acute GvHD, treatment of rejection of organ allografts and autoimmune disorders...
  10. ncbi request reprint Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation
    Katarina Le Blanc
    Division of Clinical Immunology, F79 Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Haematologica 90:438. 2005
  11. ncbi request reprint Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes
    K Le Blanc
    Division of Clinical Immunology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Scand J Immunol 60:307-15. 2004
    ..In summary, human MSC suppress proliferation of both CD4+ and CD8+ lymphocyte and decrease the expression of activation markers...
  12. doi request reprint No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells
    M Sundin
    Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Cytotherapy 10:238-42. 2008
    ..It has been suggested that MSC may be trapped in bone marrow (BM) filters during the stem cell procurement and lost from the HSC graft...
  13. doi request reprint Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation
    D Mougiakakos
    Division of Clinical Immunology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Leukemia 27:377-88. 2013
    ..The mechanisms responsible for such accumulation remain to be elucidated. It will be of great interest to prospectively investigate the influence of these cells on the graft-versus-tumor and -host reaction...
  14. ncbi request reprint Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
    K Le Blanc
    Hematology Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Leukemia 21:1733-8. 2007
    ..Thus, co-transplantation of MSC resulted in fast engraftment of absolute neutrophil count (ANC) and platelets and 100% donor chimerism, even in three patients regrafted for graft failure/rejection...
  15. doi request reprint Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells
    H Samuelsson
    Karolinska Institutet, Stockholm, Sweden
    Cytotherapy 11:129-36. 2009
    ..We investigated the impact of freezing and prolonged storage on cell viability, proliferation and immunosuppression in vitro...
  16. ncbi request reprint Immunomodulatory effects of fetal and adult mesenchymal stem cells
    K Le Blanc
    Division of Clinical Immunology, Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Cytotherapy 5:485-9. 2003
    ..These findings imply a potential role for MSC, not only in the repair of damaged tissues, but also in the manipulation of immune responses...
  17. ncbi request reprint Mesenchymal stem cells stimulate antibody secretion in human B cells
    I Rasmusson
    Karolinska Institutet, Division of Clinical Immunology, Stockholm, Sweden
    Scand J Immunol 65:336-43. 2007
    ..To conclude, MSC stimulate B-cell antibody secretion. The IgG secretion by activated B cells may be stimulated or inhibited by the addition of MSC, depending on the level of stimulation...
  18. doi request reprint Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages
    O Ringden
    Center for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, and Hematology Center, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, F79, SE 141 86 Stockholm, Sweden
    Best Pract Res Clin Haematol 24:65-72. 2011
    ..To conclude, MSCs is a novel treatment that may be used for GVHD, tissue toxicity and hemorrhages because of its immune inhibitory and anti-inflammatory effects...
  19. ncbi request reprint Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
    O Ringden
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Leukemia 21:2271-6. 2007
    ..A patient with steroid-resistant graft-versus-host disease of the gut experienced perforated diverticulitis and peritonitis that was reversed twice by MSC. MSC is a novel treatment for therapy-induced tissue toxicity...
  20. ncbi request reprint Immunologic properties of human fetal mesenchymal stem cells
    Cecilia Gotherstrom
    Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Am J Obstet Gynecol 190:239-45. 2004
    ..Mesenchymal stem cells (MSCs) can be isolated from adult bone marrow and fetal liver. We investigated the immunologic properties of undifferentiated and differentiated human fetal MSCs...
  21. ncbi request reprint No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients
    Mikael Sundin
    Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Haematologica 92:1208-15. 2007
    ..The objective of this study was to investigate whether antibodies against MSC were present after hematopoietic stem cell transplantation (HSCT) including treatment with matched or mismatched allogeneic MSC...
  22. ncbi request reprint Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum
    Katarina Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 84:1055-9. 2007
    ..MSC generated in AB-serum suppressed lymphocyte proliferation in mixed lymphocyte cultures and after stimulation with phytohemagglutinin. MSC expanded in AB-serum and FCS have similar in vitro properties...
  23. ncbi request reprint Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells
    C Gotherstrom
    Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 32:265-72. 2003
    ..fMSC inhibit lymphocyte proliferation induced by mitogens, but not alloreactivity as measured by MLC...
  24. ncbi request reprint Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual
    M Sundin
    Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Bone Marrow Transplant 37:1051-9. 2006
    ..However, MSC may be susceptible to infection if infused in a patient with CMV or HSV-1 viremia. MSC transplantation may compromise the host's defense against infectious agents...
  25. doi request reprint A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation
    O Ringden
    Division of Therapeutic Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    J Intern Med 274:153-62. 2013
    ..To our knowledge, no randomized toxicity studies have been conducted to compare myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) in allogeneic haematopoietic stem cell transplantation (HSCT)...
  26. doi request reprint Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation
    L von Bahr
    Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine Hematology Center, Karolinska University Hospital, Stockholm, Sweden
    Stem Cells 30:1575-8. 2012
    ..We conclude that MSCs appear to mediate their function through a "hit and run" mechanism. The lack of sustained engraftment limits the long-term risks of MSC therapy...
  27. ncbi request reprint Immunomodulation by mesenchymal stem cells and clinical experience
    K Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Intern Med 262:509-25. 2007
    ..Possible clinical applications include therapy-resistant severe acute graft-versus-host disease, tissue repair, treatment of rejection of organ allografts and autoimmune disorders...
  28. ncbi request reprint Functional studies of mesenchymal stem cells derived from adult human adipose tissue
    Andrea Dicker
    Department of Medicine, M63, Karolinska Institutet, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden
    Exp Cell Res 308:283-90. 2005
    ..Human adipose-tissue-derived MSCs could therefore constitute an efficient and easily obtainable renewable cellular source for studies of adipocyte biology...
  29. ncbi request reprint Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms
    Ida Rasmusson
    Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, F79, SE 141 86 Stockholm, Sweden
    Exp Cell Res 305:33-41. 2005
    ..Prostaglandins are important in the inhibition by MSCs when the T cells were activated by PHA, but not alloantigens...
  30. ncbi request reprint A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation
    Katarina Le Blanc
    Centre for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Transplantation 78:1014-20. 2004
    ..Nonmyeloablative (NM) conditioning and reduced-intensity conditioning (RIC) are increasingly used for allogeneic hematopoietic stem-cell transplantation. Such regimens have not been compared...
  31. doi request reprint Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
    Katarina Le Blanc
    Haematology Centre and Centre of Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Lancet 371:1579-86. 2008
    ..Mesenchymal stem cells modulate immune responses in vitro and in vivo. We aimed to assess whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-stem-cell transplantation...
  32. ncbi request reprint Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium
    K H Grinnemo
    Department of Cardiothoracic Surgery and Anaesthesiology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    J Thorac Cardiovasc Surg 127:1293-300. 2004
    ..It is thought that adult human mesenchymal stem cells do not induce immunoreactivity even to xenografts. We wanted to study whether adult human mesenchymal stem cells survive and engraft in experimentally induced ischemic rat myocardium...
  33. ncbi request reprint Viscoelastic and histologic properties in scarred rabbit vocal folds after mesenchymal stem cell injection
    S Hertegard
    Department of Logopedics and Phoniatrics, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Laryngoscope 116:1248-54. 2006
    ..Because MSCs are antiinflammatory and regenerate mesenchymal tissues, can MSC injection reduce vocal fold scarring after injury?..
  34. ncbi request reprint The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation
    Mikael Sundin
    Department of Laboratory Medicine, Division of Clinical Immunology F79, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Haematologica 91:1059-67. 2006
    ..The objective of this study was to determine risk factors in PTLD following HSCT in order to identify high-risk patients for surveillance, prophylaxis and treatment...
  35. ncbi request reprint Hemorrhagic cystitis: a retrospective single-center survey
    Zuzana Hassan
    Center for Allogenic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Clin Transplant 21:659-67. 2007
    ..With four risk factors, the risk of HC development was 31%. Risk factors for severe HC of grades 3-5 were aGVHD and bacteremia...
  36. ncbi request reprint HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells
    Katarina Le Blanc
    Division of Clinical Immunology, Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Exp Hematol 31:890-6. 2003
    ..Mesenchymal stem cells (MSC) do not elicit alloreactive lymphocyte responses due to immune modulations. We investigated the immunologic properties of MSC after differentiation along three lineages: bone, cartilage, and adipose...
  37. ncbi request reprint Functional characterization of human mesenchymal stem cell-derived adipocytes
    Mikael Ryden
    Department of Medicine, Center of Metabolism and Endocrinology, Karolinska Institute, Huddinge University Hospital, 141 86, Stockholm, Sweden
    Biochem Biophys Res Commun 311:391-7. 2003
    ..These systems could be of great value in adipocyte research as a renewable source of adipocytes...
  38. ncbi request reprint Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006
    ..Mesenchymal stem cells (MSC) have immunomodulatory effects. The aim was to study the effect of MSC infusion on graft-versus-host disease (GVHD)...
  39. ncbi request reprint Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells
    Cecilia Gotherstrom
    Division of Clinical Immunology, F79, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Haematologica 90:1017-26. 2005
    ..Fetal and adult MSC have similar morphology but differ in proliferative, differentiating and immunosuppressive properties. Further exploring their differences could help in choosing the right source for cellular therapy...
  40. ncbi request reprint Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives
    Olle Ringden
    Karolinska Institutet, Division of Clinical Immunology and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    APMIS 113:813-30. 2005
    ..They seem to escape the immune system and have immunomodulatory effects in vitro and in vivo. To conclude, ASCT is a potent immunotherapy...
  41. ncbi request reprint Mesenchymal stem cells: properties and role in clinical bone marrow transplantation
    Katarina Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, F79, SE 141 86 Stockholm, Sweden
    Curr Opin Immunol 18:586-91. 2006
    ..Therefore, in the future, MSCs might have implications for treatment of allograft rejection, graft-versus-host disease, autoimmune inflammatory bowel disease and other disorders in which immunomodulation and tissue repair are required...
  42. ncbi request reprint Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells
    Ida Rasmusson
    Department of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Transplantation 76:1208-13. 2003
    ..There are no publications on the effect that MSCs have on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, effector cells vital for the graft-versus-leukemia effect...
  43. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:718-25. 2006
    ..Allogeneic hematopoietic stem cell transplantation (ASCT) is a possible cure for many inherited disorders...
  44. ncbi request reprint Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood a
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology F79, Karolinska Institute, Huddinge University Hospital, SE 141 86 Stockholm, Sweden
    J Clin Oncol 22:416-23. 2004
    ..Granulocyte colony-stimulating factor (G-CSF) is given after bone marrow transplantation (BMT) to shorten the neutropenic phase. Its effects have not been evaluated in a large patient population...
  45. ncbi request reprint Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Biol Blood Marrow Transplant 11:321-34. 2005
    ..They are also of potential use in the treatment of organ transplant rejection and in autoimmune inflammatory bowel disorders where immunomodulation and tissue repair are needed...
  46. ncbi request reprint Transplantation of embryonic stem cells: possibilities and challenges
    Olle Ringden
    Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Transplantation 76:1011-2. 2003
  47. ncbi request reprint Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Biol Blood Marrow Transplant 10:128-34. 2004
    ..The 5-year survival was 72%, 48%, and 30% with 0, 1, and 2 risk factors, respectively. We concluded that unrelated hematopoietic stem cell transplantation may be improved if an optimal donor and immunosuppression are chosen...
  48. ncbi request reprint Defective platelet aggregation in polycythaemia vera is not caused by impaired calcium signaling, phospholipase D activation or decreased amounts of focal adhesion proteins
    K Le Blanc
    Department of Hematology, The Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
    Eur J Haematol 65:322-30. 2000
    ..Moreover, no apparent differences in the intracellular amounts of Fak, Syk Shc, Grb2 and rhoA could be detected between PV and control platelets...
  49. doi request reprint Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation
    Mikael Sundin
    Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 14:1172-9. 2008
    ..These findings demonstrate for the first time that persistent B19 in MSCs can infect hematopoietic stem cells and underscore the importance of monitoring B19 transmission by MSC products...
  50. ncbi request reprint Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications
    Olle T H Ringdén
    Center for Allogeneic Stem Cell Transplantation and Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Exp Hematol 33:505-12. 2005
    ..G-CSF has no effect on relapse. Available findings suggest that there is no indication to use G-CSF as prophylaxis after ASCT...
  51. ncbi request reprint Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression
    Garth Cronwright
    Department of Oncology and Pathology, Karolinska Institutet, Sweden
    Cancer Res 65:2207-15. 2005
    ..In addition, E-cadherin expression increases, mimicking a mesenchymal epithelial transition. These results afford SSX a functional role in normal stem cell migration and suggest a potentially similar function in cancer cell metastases...
  52. pmc Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies
    Katarina Le Blanc
    Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 15:1108-15. 2009
    ..81, P=.02) and aGVHD (HR 0.84, P=.05). These results indicate that LC30 is an independent prognostic factor for transplant outcome in matched unrelated SCT for myelogenous malignancies...
  53. doi request reprint Endovascular transplantation of stem cells to the injured rat CNS
    Johan Lundberg
    Department of Clinical Neuroscience, Karolinska Institutet, Department of Neuroradiology, Karolinska University Hospital, 17176 Stockholm, Sweden
    Neuroradiology 51:661-7. 2009
    ..The aim of this investigation was to analyze the effect of intra-arterial administration on cellular engraftment...
  54. ncbi request reprint Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T cells
    Olle Ringden
    Biol Blood Marrow Transplant 12:693-4. 2006
  55. doi request reprint Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
    Helen Karlsson
    Molecular Immunology Unit, Institute of Child Health, London, United Kingdom
    Blood 112:532-41. 2008
    ..These data have major implications for immunotherapy of GVHD with MSCs and suggest that the effector functions of virus-specific T cells may be retained after MSC infusion...
  56. pmc Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005
    Alan Tyndall
    Rheumatology, University Hospital Basel, Felix Platter Spital, Burgfelderstrasse 101, Basel, CH 4012, Switzerland
    Arthritis Res Ther 9:301. 2007
    ..This review summarizes the findings of a 1-day meeting devoted to the subject with the aim of coordinating efforts...
  57. ncbi request reprint Concise review: cancer/testis antigens, stem cells, and cancer
    Fabricio F Costa
    Cancer Biology and Epigenomics, Children s Memorial Research Center, 2300 Children s Plaza, Box 220, Chicago, IL 60614 3394, USA
    Stem Cells 25:707-11. 2007
    ..The clinical implications that these trials may have on the normal stem cell pools, as well as the immunologic properties of these cells, is to date poorly studied and should be considered...